Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.47 |
| ▸ | MAOB | P27338 | 6/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | AGXT | P21549 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321452 | 0.85 | MAOB (0.48) | MAOBIDO1AGXTLMNAL3MBTL1 | |
| SCHEMBL693190 | 0.85 | MRGPRX4 (0.51) | MAOBIDO1AGXTMRGPRX4 | |
| SCHEMBL5475735 | 0.83 | MAOB (0.51) | MAOBIDO1AGXTLMNAL3MBTL1 | |
| SCHEMBL17975674 | 0.82 | ALDH1A1 (0.43) | MAOBIDO1AGXT | |
| SCHEMBL3324129 | 0.82 | MAOB (0.54) | EGFRMAOBIDO1AGXTLMNA | |
| SCHEMBL1446254 | 0.82 | HPGD (0.46) | MAOBL3MBTL1MRGPRX4 | |
| SCHEMBL28102426 | 0.81 | MRGPRX4 (0.67) | MAOBMRGPRX4 | |
| SCHEMBL5263840 | 0.80 | MEN1 (0.60) | EGFRERBB2MAOBIDO1AGXT | |
| SCHEMBL29434222 | 0.80 | MEN1 (0.60) | EGFRERBB2MAOBIDO1AGXT | |
| SCHEMBL694220 | 0.79 | NPC1 (0.49) | IDO1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112759583-B | Quinoline derivative containing furyl and preparation method and application thereof | 河南省医药科学研究院 | 2022-10-11 | — | — | CN | claimed |
| CN-112694439-B | Phenyl acrylamide quinoline derivative and preparation method and application thereof | 河南省医药科学研究院 | 2022-08-30 | — | — | CN | claimed |
| CN-112759583-A | Quinoline derivative containing furyl and preparation method and application thereof | 河南省医药科学研究院 | 2021-05-07 | — | — | CN | claimed |
| CN-112694439-A | Phenyl acrylamide quinoline derivative and preparation method and application thereof | 河南省医药科学研究院 | 2021-04-23 | — | — | CN | claimed |
| CN-112625025-A | Pyridyl substituted quinoline derivative and its prepn and use | 河南省医药科学研究院 | 2021-04-09 | — | — | CN | claimed |
| CN-106892898-B | Azasugar-derived quinazolines | 陕西师范大学 | 2021-02-05 | — | — | CN | claimed |
| CN-107674059-B | Benzaheteroaromatic ring compound and preparation method and application thereof | 中国药科大学 | 2020-04-14 | — | — | CN | claimed |
| EP-3089961-B1 | PROCESS FOR THE MANUFACTURE OF (E)-4-N,N-DIALKYLAMINO CROTONIC ACID IN HX SALT FORM AND USE THEREOF FOR SYNTHESIS OF EGFR TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-07-11 | — | — | EP | claimed |
| EP-3089961-A1 | PROCESS FOR THE MANUFACTURE OF (E)-4-N,N-DIALKYLAMINO CROTONIC ACID IN HX SALT FORM AND USE THEREOF FOR SYNTHESIS OF EGFR TYROSINE KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-11-09 | — | — | EP | claimed |
| US-9242965-B2 | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | claimed |
| EP-1460072-B1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXO GROUP LTD (GB) | 2006-04-05 | — | — | EP | claimed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | claimed |
| US-20050130995-A1 | Chlorinating quinazolin-4-one in solvent in presence of a base; then reacting with an amine compound | UBE INDUSTRIES, LTD. (JP) | 2005-06-16 | — | — | US | claimed |
| EP-1492536-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-05 | — | — | EP | claimed |
| EP-1481971-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | Ube Industries, Ltd. (JP) | 2004-12-01 | — | — | EP | claimed |
| EP-1460072-A1 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-09-22 | — | — | EP | claimed |
| EP-1454907-A1 | Quninazoline and pyridopyrmidine derivatives | Glaxo Group Limited (GB) | 2004-09-08 | — | — | EP | claimed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| WO-2003082290-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130995-A1 | Chlorinating quinazolin-4-one in solvent in presence of a base; then reacting with an amine compound | HRH4, HRH3, H1-4 | EGFR 543/4885ERBB2 231/4885MAOB 462/4885 |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | EGFR 1233/4885ERBB2 1107/4885MAOB 262/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | EGFR 221/4885ERBB2 163/4885MAOB 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.